OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced it will be presenting positive preclinical data detailing delivery of interleukin-12 (IL-12) with the ON-BOARD™ platform at the 38^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 1-5, 2023 in San Diego, California.

ON-BOARD™ is an ultra pH-sensitive tumor delivery platform designed to minimize systemic exposure and toxicity by protecting oncology intervention payloads and releasing them specifically in the acidic tumor microenvironment. The poster presentation will detail encapsulation and delivery of IL-12, a potent pleiotropic cytokine, using ON-BOARD™ in immunocompetent mice.

Presentation Overview

Title: Encapsulation of IL-12 with an ultra pH-sensitive tumor delivery platform improves tolerability and promotes antitumor response in a preclinical model

Presenter: Jason Miller, Ph.D., Associate Director, Research Pipeline Development, OncoNano Medicine

Date: Friday, November 3, 2023

Time: 9:00 a.m. – 7:00 p.m. PT

Location: Exhibit Hall B – San Diego Convention Center

Poster Number: 1147-B

About OncoNano Medicine

OncoNano Medicine is developing a new class of cancer products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat solid tumors with high specificity. Our polymeric micelles are designed to efficiently deliver oncology payloads to the tumor microenvironment for an enhanced therapeutic index. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, a platform of immuno-oncology therapeutics that activate and guide the body’s immune system to target cancer, and agents for real-time image guided surgery.

ONM-501, OncoNano’s first therapeutic program, is a next generation dual-activating STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the fourth quarter of 2023. OncoNano’s second therapeutic development program is ONM-412, the highly potent pro-inflammatory cytokine, interleukin-12 (IL-12), encapsulated in the ON-BOARD™ polymeric micelle system. Additionally, the ON-BOARD™ platform has been used for pegsitacianine, a novel fluorescent nanoprobe that is being studied as a real-time surgical imaging agent for use in multiple cancer surgeries and is advancing towards a pivotal clinical trial to aid in tumor detection of peritoneal carcinomatosis. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas (CPRIT). Learn more at www.OncoNano.com.

Contacts

MacDougall Advisors

Lauren Arnold

781-235-3060

[email protected]